• Submitted by: manso
• Business and Economy
• 03 / 22 / 2011

---

2011.03.21 / radiorebelde.Havana, Cuba.- Thailand started to commercialize a monoclonal antibody manufactured in Cuba for the treatment of malignant head, neck, brain and esophagus tumors, diplomatic sources in Bangkok reported.

The antitumor product called Nimotuzumab and commercialized as TheraCIM was well received by doctors and oncologists from Thailand, Indonesia and Philippines, PL reported.

TheraCIM is manufactured by the Molecular Immunology Center of Cuba and has been registered in 26 countries, mostly of Latin America and Asia. Other commercial names are Theraloc and BIOMab.

The Molecular Immunology Center was inaugurated in 1994 with the main mission of obtaining and producing new biopharmaceutical drugs for the treatment of cancer and other non-transmissible chronic diseases for domestic use.

Thailand is the fourth Asian country to register the Cuban product, following China, Indonesia and Philippines.

Meanwhile, the Innogene Kalbiotec firm, which offices in Indonesia and Singapore will be in charge of the commercialization of TheraCIM in southeastern Asia.

Director of Thailand’s National Institute against Cancer, Thiravud Khuhaprema, highlighted the advantages of the Cuban medicament such as the fact that it doesn’t produce side effects as oppose to traditional medicaments against cancer, and noted its high effectiveness.(ACN)